Efficacy of Newcastle disease LaSota vaccine-induced hemagglutination inhibition antibodies against challenges with heterologous virulent strains of genotypes VII and IX

• Published in: Veterinary immunology and immunopathology 2023-05, Vol.259, p.110591-110591, Article 110591
• Main Authors: Liu, Mei, Shen, Xinyue, Li, Jianmei, Yu, Yan, Fan, Jianhua, Jia, Xuebo, Dai, Yabin
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Viral; Chickens; Efficacy; Genotype; Hemagglutination; Hemagglutination inhibition antibody; LaSota vaccine; Newcastle Disease - prevention & control; Newcastle disease virus; Newcastle disease virus - genetics; Poultry Diseases - prevention & control; Viral Vaccines; Virus Shedding
• ISSN: 0165-2427; 1873-2534
• DOI: 10.1016/j.vetimm.2023.110591

Newcastle disease (ND), caused by virulent Newcastle disease virus (NDV), still remains one of the most important avian diseases affecting the poultry industry worldwide, despite intensive vaccination programs have been implemented in many countries. All NDV isolates characterized to date are of one serotype and classified into classes I and II, with class II being further divided into twenty-one genotypes. Antigenic and genetic diversity is observed among the different genotypes. Current commercially available vaccines belonging to genotypes I and II are genetically divergent from strains that caused ND outbreaks worldwide in the last two decades. Reports of vaccination failures on their insufficient ability to inhibit infection or virus shedding have created renewed interest in developing vaccines homologous to virulent NDV circulating in the field. In this study, after vaccination with the most widely used LaSota vaccine (genotype II), chickens with different hemagglutination inhibition (HI) antibody levels were challenged with heterologous virulent NDV strains of genotypes VII and IX to evaluate how antibody levels relate to clinical protection and infection or virus shedding. Under the experimental condition, LaSota vaccine could fully protect birds from morbidity and mortality, but higher antibody levels were required to inhibit virus shedding. The number of birds shedding virus generally tended to decrease as the HI antibody titers increase in vaccinated birds. When the HI antibody titers reached ≥ 13 log2 and ≥ 10 log2, the virus shedding from JSC0804 strain (genotype VII) and F48E8 strain (genotype IX) could be completely inhibited, respectively, but it may be difficult to ensure that all individuals reach and maintain those levels in chicken flocks vaccinated according to routine procedure. Furthermore, the virus shedding in vaccinated birds was correlated with the amino acid similarity between the vaccine and challenge strains; more similarity, less virus shedding. The results obtained highlight that stringent biosecurity measures combined with vaccination are crucial for chicken farms to maintain a virulent NDV-free status. •Commercial ND vaccine strains are genetically diverged from circulating strains.•LaSota vaccine can afford clinical protection from genotypes VII and IX strains.•Very high HI antibody levels are required for blocking virus shedding or infection.•Virus shedding is correlated with the amino acid similarity between vaccine and